Platinum (IV) derivative with adamantylamine-LA-12-represents a new generation of highly efficient anti-cancer drug derived from cisplatin and is currently in the final stage of phase I clinical trials. Understanding the specific mechanisms of its effects on cell cycle is necessary for defining the mode of action of LA-12. In this study, we characterized the ability of LA-12 to induce cell cycle perturbations in ovarian cancer cell line A2780 as compared to equitoxic cisplatin treatment. LA-12 induced a permanent accumulation of A2780 cells in S phase while cisplatin caused G2/M arrest at 24-h time point, where we also detected an increased expression of Gadd45alpha protein. Although both derivatives induced a rapid increase of p53 expression, this was not associated with a down-regulation of Mdm2 protein. Increased expression of p21(Cip1/WAF1) protein and its association with cyclins A and B1 suggested that this cyclin-dependent kinase inhibitor might contribute significantly to the observed perturbations of cell cycle. The results of this study provide insight into the mechanism of action of platinum-based derivative with adamantylamine on cell cycle in ovarian cancer cells. The differences between effects of LA-12 and cisplatin suggest that more attention should be paid to elucidation of modes of action of novel platinum(IV) complexes at cellular level.

Department of Cytokinetics Institute of Biophysics Academy of Sciences of the Czech Republic Královopolská 135 CZ 612 65 Brno Czech Republic

Zobrazit více v PubMed

Science. 1996 Dec 6;274(5293):1664-72 PubMed

Anticancer Drugs. 2006 Feb;17(2):201-6 PubMed

Mol Cancer Ther. 2002 Oct;1(12):1067-78 PubMed

Cancer Res. 1987 Jan 15;47(2):414-8 PubMed

Cell. 1998 Oct 2;95(1):5-8 PubMed

J Med Chem. 2004 Jan 29;47(3):761-3 PubMed

EMBO J. 1993 Feb;12 (2):461-8 PubMed

Oncogene. 1994 Dec;9(12):3743-51 PubMed

FEBS Lett. 2001 Feb 16;490(3):117-22 PubMed

J Immunol Methods. 1992 Jul 6;151(1-2):237-44 PubMed

Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3706-11 PubMed

Biochem Biophys Res Commun. 1994 Mar 15;199(2):937-43 PubMed

Biochem Pharmacol. 2005 Feb 1;69(3):373-83 PubMed

Semin Oncol. 1984 Sep;11(3):285-98 PubMed

Cell. 1993 Nov 19;75(4):817-25 PubMed

Prog Nucleic Acid Res Mol Biol. 2001;67:93-130 PubMed

Oncogene. 1995 Oct 5;11(7):1217-28 PubMed

Science. 1994 Nov 25;266(5189):1376-80 PubMed

Met Ions Biol Syst. 2004;42:297-322 PubMed

Int J Pharm. 2005 Jan 6;288(1):123-9 PubMed

Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):679-85 PubMed

Cell. 1992 Nov 13;71(4):587-97 PubMed

Nature. 1997 May 15;387(6630):296-9 PubMed

Cancer Invest. 1993;11(3):264-75 PubMed

Eur J Cancer. 1998 Sep;34(10):1535-42 PubMed

Nature. 1993 Dec 16;366(6456):701-4 PubMed

Br J Cancer. 1996 Oct;74(7):1037-45 PubMed

Neoplasma. 2002;49(6):362-7 PubMed

Cell. 1995 Jan 27;80(2):293-9 PubMed

Oncogene. 1999 May 6;18(18):2892-900 PubMed

Trends Cell Biol. 2003 Feb;13(2):65-70 PubMed

J Med. 1993;24(4-5):209-65 PubMed

Cytometry. 1997 Jan 1;27(1):54-64 PubMed

Gynecol Oncol. 2006 Jul;102(1):32-40 PubMed

Expert Rev Anticancer Ther. 2006 Jul;6(7):973-82 PubMed

Chem Rev. 1999 Sep 8;99(9):2451-66 PubMed

Anticancer Drugs. 2004 Jun;15(5):537-43 PubMed

Chem Biol Interact. 1999 Jan 29;117(2):99-115 PubMed

Cancer Res. 1988 Oct 15;48(20):5713-6 PubMed

Prog Cell Cycle Res. 1996;2:165-73 PubMed

Neoplasia. 2000 Jul-Aug;2(4):291-9 PubMed

Oncogene. 2001 Apr 5;20(15):1923-7 PubMed

Anticancer Drugs. 2005 Jul;16(6):653-7 PubMed

Cancer Res. 1988 Dec 1;48(23):6703-7 PubMed

Oncogene. 2003 Oct 20;22(47):7265-79 PubMed

Mol Pharmacol. 2006 Nov;70(5):1708-19 PubMed

Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells

The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12

The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin